Literature DB >> 29263056

Pyrazinamide Resistance among Multidrug-Resistant Mycobacterium tuberculosis Clinical Isolates in Myanmar.

Wah Wah Aung1, Phyu Win Ei1, Wint Wint Nyunt2, Mi Mi Htwe1, Su Mon Win1, Kay Thi Aye1, Aye Su Mon1, Si Thu Aung2, Chulhun L Chang3, Jong Seok Lee4.   

Abstract

Entities:  

Keywords:  MDR-TB; Myanmar; XDR-TB; pyrazinamide

Mesh：

Substances：

Year:  2018        PMID： 29263056      PMCID： PMC5826152          DOI： 10.1128/AAC.01984-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  7 in total

1.  Testing of susceptibility of Mycobacterium tuberculosis to pyrazinamide with the nonradiometric BACTEC MGIT 960 system.

Authors:  Gaby E Pfyffer; Frantiska Palicova; Sabine Rüsch-Gerdes
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

Review 2.  The curious characteristics of pyrazinamide: a review.

Authors:  Y Zhang; D Mitchison
Journal:  Int J Tuberc Lung Dis       Date:  2003-01       Impact factor: 2.373

3.  Comparison of phenotypic and genotypic methods for pyrazinamide susceptibility testing.

Authors:  Shubhada Shenai; Camilla Rodrigues; Meeta Sadani; Nesline Sukhadia; Ajita Mehta
Journal:  Indian J Tuberc       Date:  2009-04

4.  Pyrazinamide resistance and pncA gene mutations in Mycobacterium tuberculosis.

Authors:  Pontus Juréen; Jim Werngren; Juan-Carlos Toro; Sven Hoffner
Journal:  Antimicrob Agents Chemother       Date:  2008-03-03       Impact factor: 5.191

5.  Mycobacterium tuberculosis pyrazinamide resistance determinants: a multicenter study.

Authors:  Paolo Miotto; Andrea M Cabibbe; Silke Feuerriegel; Nicola Casali; Francis Drobniewski; Yulia Rodionova; Daiva Bakonyte; Petras Stakenas; Edita Pimkina; Ewa Augustynowicz-Kopeć; Massimo Degano; Alessandro Ambrosi; Sven Hoffner; Mikael Mansjö; Jim Werngren; Sabine Rüsch-Gerdes; Stefan Niemann; Daniela M Cirillo
Journal:  mBio       Date:  2014-10-21       Impact factor: 7.867

6.  Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project.

Authors:  Matteo Zignol; Anna S Dean; Natavan Alikhanova; Sönke Andres; Andrea Maurizio Cabibbe; Daniela Maria Cirillo; Andrei Dadu; Andries Dreyer; Michèle Driesen; Christopher Gilpin; Rumina Hasan; Zahra Hasan; Sven Hoffner; Ashaque Husain; Alamdar Hussain; Nazir Ismail; Mostofa Kamal; Mikael Mansjö; Lindiwe Mvusi; Stefan Niemann; Shaheed V Omar; Ejaz Qadeer; Leen Rigouts; Sabine Ruesch-Gerdes; Marco Schito; Mehriban Seyfaddinova; Alena Skrahina; Sabira Tahseen; William A Wells; Ya Diul Mukadi; Michael Kimerling; Katherine Floyd; Karin Weyer; Mario C Raviglione
Journal:  Lancet Infect Dis       Date:  2016-07-07       Impact factor: 25.071

7.  Tuberculosis drug resistance mutation database.

Authors:  Andreas Sandgren; Michael Strong; Preetika Muthukrishnan; Brian K Weiner; George M Church; Megan B Murray
Journal:  PLoS Med       Date:  2009-02-10       Impact factor: 11.069
  7 in total
  2 in total

Review 1.  The Bewildering Antitubercular Action of Pyrazinamide.

Authors:  Elise A Lamont; Nicholas A Dillon; Anthony D Baughn
Journal:  Microbiol Mol Biol Rev       Date:  2020-03-04       Impact factor: 11.056

2.  Resistance To First-Line Antituberculosis Drugs And Prevalence Of pncA Mutations In Clinical Isolates Of Mycobacterium tuberculosis From Zunyi, Guizhou Province Of China.

Authors:  Zhimin Cao; Yuanbo Lan; Ling Chen; Min Xiang; Zhiyuan Peng; Jianyong Zhang; Hong Zhang
Journal:  Infect Drug Resist       Date:  2019-09-30       Impact factor: 4.003
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.